[
  {
    "ts": null,
    "headline": "GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel",
    "summary": "Gilead is set to acquire Arcellx for $7.8B, gaining full control of anito-cel and boosting its cell therapy pipeline amid rising competition.",
    "url": "https://finnhub.io/api/news?id=a2967c8953096887d2a6ab8cd570a25bfd46fd9a13b376ff50faccf3de59e7c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771958220,
      "headline": "GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel",
      "id": 139201652,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Gilead is set to acquire Arcellx for $7.8B, gaining full control of anito-cel and boosting its cell therapy pipeline amid rising competition.",
      "url": "https://finnhub.io/api/news?id=a2967c8953096887d2a6ab8cd570a25bfd46fd9a13b376ff50faccf3de59e7c4"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=3624285aeb3bd33b02b92939382034441217f5bbc46798baa21272a2be44604f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771941606,
      "headline": "Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know",
      "id": 139197444,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=3624285aeb3bd33b02b92939382034441217f5bbc46798baa21272a2be44604f"
    }
  },
  {
    "ts": null,
    "headline": "FDA Accepts Bristol Myers Squibb (BMY) NDA for Iberdomide With Priority Review",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best value stocks to buy now. On February 17, Bristol Myers Squibb announced that the FDA accepted its NDA for iberdomide, which is an investigational treatment for patients with relapsed or refractory multiple myeloma/RRMM. If approved, iberdomide would become the first in a new class of oral […]",
    "url": "https://finnhub.io/api/news?id=85a74d1d5b6787cc5030d9f226410281dda51eab9df2c0a4f37af19dbbc2b8a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771917087,
      "headline": "FDA Accepts Bristol Myers Squibb (BMY) NDA for Iberdomide With Priority Review",
      "id": 139191742,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best value stocks to buy now. On February 17, Bristol Myers Squibb announced that the FDA accepted its NDA for iberdomide, which is an investigational treatment for patients with relapsed or refractory multiple myeloma/RRMM. If approved, iberdomide would become the first in a new class of oral […]",
      "url": "https://finnhub.io/api/news?id=85a74d1d5b6787cc5030d9f226410281dda51eab9df2c0a4f37af19dbbc2b8a4"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Bristol Myers Squibb (BMY) Valuation After Key Multiple Myeloma And Alpha Thalassemia Updates",
    "summary": "Investor interest in Bristol-Myers Squibb (BMY) has picked up after a cluster of clinical and regulatory milestones, including FDA Breakthrough Therapy Designation and Priority Review for iberdomide in multiple myeloma, as well as strong Phase 2 data for Reblozyl in alpha-thalassemia. See our latest analysis for Bristol-Myers Squibb. The recent clinical wins and upbeat analyst commentary appear to be contributing to building momentum, with a 24.87% 90 day share price return and a 21.20% five...",
    "url": "https://finnhub.io/api/news?id=c1314eabc44941b3274f74c310c0f932ffdeca313d1b49310fe34dccd5f1f358",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771909678,
      "headline": "Assessing Bristol Myers Squibb (BMY) Valuation After Key Multiple Myeloma And Alpha Thalassemia Updates",
      "id": 139190989,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Investor interest in Bristol-Myers Squibb (BMY) has picked up after a cluster of clinical and regulatory milestones, including FDA Breakthrough Therapy Designation and Priority Review for iberdomide in multiple myeloma, as well as strong Phase 2 data for Reblozyl in alpha-thalassemia. See our latest analysis for Bristol-Myers Squibb. The recent clinical wins and upbeat analyst commentary appear to be contributing to building momentum, with a 24.87% 90 day share price return and a 21.20% five...",
      "url": "https://finnhub.io/api/news?id=c1314eabc44941b3274f74c310c0f932ffdeca313d1b49310fe34dccd5f1f358"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons to Avoid BMY and 1 Stock to Buy Instead",
    "summary": "Over the past six months, Bristol-Myers Squibb has been a great trade, beating the S&P 500 by 22.8%. Its stock price has climbed to $61.33, representing a healthy 30.1% increase. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.",
    "url": "https://finnhub.io/api/news?id=e7fb0314ae24c720e330dd009cabae01d6b5f1a1fc7b2b608bf69527261efe80",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771905893,
      "headline": "3 Reasons to Avoid BMY and 1 Stock to Buy Instead",
      "id": 139193324,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Over the past six months, Bristol-Myers Squibb has been a great trade, beating the S&P 500 by 22.8%. Its stock price has climbed to $61.33, representing a healthy 30.1% increase. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.",
      "url": "https://finnhub.io/api/news?id=e7fb0314ae24c720e330dd009cabae01d6b5f1a1fc7b2b608bf69527261efe80"
    }
  },
  {
    "ts": null,
    "headline": "FDA Review Of Iberdomide Puts Fresh Focus On Bristol Myers Valuation",
    "summary": "FDA accepts Bristol Myers Squibb’s New Drug Application for iberdomide in relapsed or refractory multiple myeloma. The filing has been granted Breakthrough Therapy Designation and Priority Review. Iberdomide is being evaluated for patients with a hard to treat blood cancer where curative options remain limited. For Bristol Myers Squibb, NYSE:BMY, this regulatory step comes at a time when the shares trade around $61.25. Recent returns show the stock up 12.1% over the past 30 days and 14.6%...",
    "url": "https://finnhub.io/api/news?id=dbc41d5234ce53315bba277e74532c2e2cbdde62613228727f9cb34c493d8e94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771899081,
      "headline": "FDA Review Of Iberdomide Puts Fresh Focus On Bristol Myers Valuation",
      "id": 139190284,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "FDA accepts Bristol Myers Squibb’s New Drug Application for iberdomide in relapsed or refractory multiple myeloma. The filing has been granted Breakthrough Therapy Designation and Priority Review. Iberdomide is being evaluated for patients with a hard to treat blood cancer where curative options remain limited. For Bristol Myers Squibb, NYSE:BMY, this regulatory step comes at a time when the shares trade around $61.25. Recent returns show the stock up 12.1% over the past 30 days and 14.6%...",
      "url": "https://finnhub.io/api/news?id=dbc41d5234ce53315bba277e74532c2e2cbdde62613228727f9cb34c493d8e94"
    }
  }
]